Clinical Trial Update: Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 clinical trial exploring how dapagliflozin affects urinary proteomic patterns in patients with type 2 diabetes and diabetic nephropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Peter Rossing | Conditions: Type 2 Diabetes, Diabetic Nephropathy | Phase 4 | Status: COMPLETED